<!doctype html>

<html lang="zh-CN">
	<head>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width,initial-scale=1" />

		<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png" />
		<link rel="icon" type="image/png" sizes="16x16" href="/favicon@16x16.png" />

		<link rel="alternate" type="application/rss+xml" title="RSS" href="/rss.xml" />

		<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@4/tex-mml-chtml.js"></script>

		<title>
			
秋槭与石桥都消失不见 - Stahl&#x27;s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications 章5笔记

		</title>

		<link rel="stylesheet" href="/font.css" />
		<link rel="stylesheet" href="/base.css" />
		
<link rel="stylesheet" href="/page.css" />

	</head>

	<body>
		
<nav>
    <ul>
        <li>
            <a href="/">home</a>
        </li>
        <li>
            <a href="/blog/">blog</a>
        </li>
        <li>
            <a>图片库</a>
        </li>
        <li>
            <a>关于本站</a>
        </li>
    </ul>
</nav>

<section>
    <h1>
        Stahl&#x27;s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications 章5笔记
    </h1>
</section>

<section>
    <p>
        主要介绍了抗精神病药（D2阻滞药、D2&#x2F;5HT2A阻滞药和D2&#x2F;5HT1A部分激动药），还有一些新鲜的抗精神病药（5HT2A阻滞药、D3阻滞药、TAAR1激动药、M4&#x2F;M1激动药、DAO抑制药、磷酸二酯酶9&#x2F;10抑制药）、治疗TD的药（VMAT2阻滞药）。
    </p>
</section>


    <section class="bordered">
        <ul>
            
                <li>
                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-targeting-dopamine-and-serotonin-receptors-for-psychosis-mood-and-beyond-so-called-antipsychotics-zuo-yong-yu-duo-ba-e-he-5-htshou-ti-zhi-liao-jing-shen-bing-xing-zheng-zhuang-he-xin-jing-zheng-zhuang-deng-de-kang-jing-shen-bing-yao"> 5 Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called &quot;Antipsychotics&quot; 作用于多巴胺和5-HT受体治疗精神病性症状和心境症状等的“抗精神病药” </a>
                    
                        <ul>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-1-targeting-mesolimbic-mesostriatal-dopamine-d2-receptors-causes-antipsychotic-actions-zuo-yong-yu-zhong-nao-bian-yuan-zhong-nao-wen-zhuang-ti-d2shou-ti-zao-cheng-kang-jing-shen-bing-xiao-ying"> 5.1 Targeting Mesolimbic&#x2F;Mesostriatal Dopamine D2 Receptors Causes Antipsychotic Actions 作用于中脑边缘&#x2F;中脑纹状体D2受体造成抗精神病效应 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-2-targeting-dopamine-d2-receptors-in-mesolimbic-mesostriatal-and-mesocortical-pathways-causes-secondary-negative-symptoms-zuo-yong-yu-zhong-nao-bian-yuan-zhong-nao-wen-zhuang-ti-he-zhong-nao-pi-zhi-d2shou-ti-zao-cheng-ji-fa-xing-yin-xing-zheng-zhuang"> 5.2 Targeting Dopamine D2 Receptors in Mesolimbic&#x2F;Mesostriatal and Mesocortical Pathways Causes Secondary Negative Symptoms 作用于中脑边缘&#x2F;中脑纹状体和中脑皮质D2受体造成继发性阴性症状 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-3-targeting-tuberoinfundibular-dopamine-d2-receptors-causes-elevation-of-prolactin-zuo-yong-yu-jie-jie-lou-dou-d2shou-ti-zao-cheng-cui-ru-su-sheng-gao"> 5.3 Targeting Tuberoinfundibular Dopamine D2 Receptors Causes Elevation of Prolactin 作用于结节漏斗D2受体造成催乳素升高 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-4-targeting-nigrostriatal-dopamine-d2-receptors-causes-motor-side-effects-zuo-yong-yu-hei-zhi-wen-zhuang-ti-d2shou-ti-zao-cheng-yun-dong-fu-xiao-ying"> 5.4 Targeting Nigrostriatal Dopamine D2 Receptors Causes Motor Side Effects 作用于黑质纹状体D2受体造成运动副效应 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-5-drugs-targeting-dopamine-d2-receptors-so-called-first-generation-or-conventional-antipsychotics-zuo-yong-yu-d2shou-ti-de-di-yi-dai-dian-xing-kang-jing-shen-bing-yao"> 5.5 Drugs Targeting Dopamine D2 Receptors: So-Called First Generation or Conventional &quot;Antipsychotics&quot; 作用于D2受体的“第一代&#x2F;典型抗精神病药” </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-6-drugs-targeting-serotonin-2a-receptors-with-or-without-simultaneously-targeting-dopamine-d2-receptors-zuo-yong-yu-5ht2ashou-ti-he-fei-zuo-yong-yu-d2shou-ti-de-yao"> 5.6 Drugs Targeting Serotonin 2A Receptors with or without Simultaneously Targeting Dopamine D2 Receptors 作用于5HT2A受体和&#x2F;非作用于D2受体的药 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-7-drugs-targeting-serotonin-1a-receptors-and-dopamine-d2-receptors-as-partial-agonists-5ht1a-d2bu-fen-ji-dong-yao"> 5.7 Drugs Targeting Serotonin 1A Receptors and Dopamine D2 Receptors as Partial Agonists 5HT1A&#x2F;D2部分激动药 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-8-links-between-receptor-binding-properties-of-drugs-used-to-treat-psychosis-and-other-therapeutic-actions-and-side-effects-shou-ti-he-xiao-ying-de-guan-lian"> 5.8 Links between Receptor Binding Properties of Drugs Used to Treat Psychosis and Other Therapeutic Actions and Side Effects 受体和效应的关联 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-9-pharmacological-properties-of-selected-individual-first-generation-d2-antagonists-bu-fen-d2zu-zhi-yao-de-yao-li-xue-xing-zhi"> 5.9 Pharmacological Properties of Selected Individual First-Generation D2 Antagonists 部分D2阻滞药的药理学性质 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-10-an-overview-of-the-pharmacological-properties-of-individual-5ht2a-d2-antagonists-and-d2-5ht1a-partial-agonists-the-pines-peens-many-dones-and-a-rone-two-pips-and-a-rip-ge-d2-5ht2azu-zhi-yao-he-d2-5ht1abu-fen-ji-dong-yao-de-yao-li-xue-xing-zhi-gai-shu"> 5.10 An Overview of the Pharmacological Properties of Individual 5HT2A&#x2F;D2 Antagonists and D2&#x2F;5HT1A Partial Agonists: The Pines (Peens), Many Dones and a Rone, Two Pips and a Rip 各D2&#x2F;5HT2A阻滞药和D2&#x2F;5HT1A部分激动药的药理学性质概述 </a>
                                </li>
                            
                                <li>
                                    <a href="https://maple-and-stonebridge.github.io/blog/20251219-psychopharmacology-note-chapter-5/#5-11-future-treatments-for-schizophrenia-jing-shen-fen-lie-zheng-zhi-liao-zhan-wang"> 5.11 Future Treatments for Schizophrenia 精神分裂症治疗展望 </a>
                                </li>
                            
                        </ul>
                    
                </li>
            
        </ul>
    </section>


<section class="bordered">
    <p><a href="https://maple-and-stonebridge.github.io/blog/20250919-psychopharmacology-note-index/">&lt; 本书笔记目录</a></p>
<hr />
<h1 id="5-targeting-dopamine-and-serotonin-receptors-for-psychosis-mood-and-beyond-so-called-antipsychotics-zuo-yong-yu-duo-ba-e-he-5-htshou-ti-zhi-liao-jing-shen-bing-xing-zheng-zhuang-he-xin-jing-zheng-zhuang-deng-de-kang-jing-shen-bing-yao">5 Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called "Antipsychotics" 作用于多巴胺和5-HT受体治疗精神病性症状和心境症状等的“抗精神病药”</h1>
<ul>
<li>1950年代，第1种被偶然发现具有抗精神病作用的非镇静药是氯丙嗪 chlorpromazine ，起初作为抗组胺药被开发。</li>
<li>1970年代发现药的抗精神病作用由D2阻滞介导。</li>
<li>新药通常在D2阻滞的基础上加入了5HT2A阻滞或5HT1A部分激动作用，或将D2阻滞优化为D2部分激动，甚至只保留5HT2A阻滞而放弃D2阻滞。</li>
</ul>
<h2 id="5-1-targeting-mesolimbic-mesostriatal-dopamine-d2-receptors-causes-antipsychotic-actions-zuo-yong-yu-zhong-nao-bian-yuan-zhong-nao-wen-zhuang-ti-d2shou-ti-zao-cheng-kang-jing-shen-bing-xiao-ying">5.1 Targeting Mesolimbic/Mesostriatal Dopamine D2 Receptors Causes Antipsychotic Actions 作用于中脑边缘/中脑纹状体D2受体造成抗精神病效应</h2>
<p>请参阅<a href="/blog/20251106-psychopharmacology-note-chapter-4/#duo-ba-e-shen-jing-di-zhi-wang-luo">上章</a>。</p>
<h2 id="5-2-targeting-dopamine-d2-receptors-in-mesolimbic-mesostriatal-and-mesocortical-pathways-causes-secondary-negative-symptoms-zuo-yong-yu-zhong-nao-bian-yuan-zhong-nao-wen-zhuang-ti-he-zhong-nao-pi-zhi-d2shou-ti-zao-cheng-ji-fa-xing-yin-xing-zheng-zhuang">5.2 Targeting Dopamine D2 Receptors in Mesolimbic/Mesostriatal and Mesocortical Pathways Causes Secondary Negative Symptoms 作用于中脑边缘/中脑纹状体和中脑皮质D2受体造成继发性阴性症状</h2>
<ul>
<li>由于中脑边缘/中脑纹状体通路介导动机和奖赏，因此本通路D2阻滞可导致淡漠、快感丧失、动机兴趣缺乏等阴性症状，即 <strong>继发性阴性症状 secondary negative symptoms</strong> 。</li>
<li>中脑皮质通路D2阻滞可导致继发性阴性症状，以及认知症状和情感症状的加重。</li>
</ul>
<h2 id="5-3-targeting-tuberoinfundibular-dopamine-d2-receptors-causes-elevation-of-prolactin-zuo-yong-yu-jie-jie-lou-dou-d2shou-ti-zao-cheng-cui-ru-su-sheng-gao">5.3 Targeting Tuberoinfundibular Dopamine D2 Receptors Causes Elevation of Prolactin 作用于结节漏斗D2受体造成催乳素升高</h2>
<ul>
<li>由于结节漏斗通路激活抑制泌乳素分泌，因此本通路D2阻滞可造成高泌乳素血症，导致溢乳、乳房女性化、闭经、不育、性功能障碍和体重增加等。在未进行雌激素替代治疗的闭经女性中可造成骨脱矿。</li>
</ul>
<h2 id="5-4-targeting-nigrostriatal-dopamine-d2-receptors-causes-motor-side-effects-zuo-yong-yu-hei-zhi-wen-zhuang-ti-d2shou-ti-zao-cheng-yun-dong-fu-xiao-ying">5.4 Targeting Nigrostriatal Dopamine D2 Receptors Causes Motor Side Effects 作用于黑质纹状体D2受体造成运动副效应</h2>
<ul>
<li>黑质纹状体通路—间接通路D2急性阻滞可造成药源性Parkinson症、静坐不能和肌张力障碍。慢性阻滞可造成迟发性运动障碍。以上统称 <strong>锥体外系症状 extrapyramidal symptoms, EPS</strong> 。</li>
</ul>
<h3 id="yao-yuan-xing-parkinsonzheng">药源性Parkinson症</h3>
<ul>
<li><strong>药源性Parkinson症 drug-induced Parkinsonism, DIP</strong> 是震颤、肌肉僵硬、运动徐缓或运动不能。</li>
<li><span class=""></span>治疗<span class=""></span> ：传统上使用抗胆碱药。 <span class=""></span>可能机制<span class=""></span> ：黑质纹状体D2阻滞导致纹状体乙酰胆碱能神经元去抑制，由其支配的纹状体GABA能神经元可产生功能异常，进而介导DIP。M（特别是M1）阻滞可对抗该作用。抗胆碱副作用较强，且一些D2阻滞药本身有抗胆碱活性。
<ul>
<li>可使用金刚烷胺 amantadine 治疗， <span class=""></span>可能机制<span class=""></span> ：弱NMDA阻滞。</li>
</ul>
</li>
</ul>
<h3 id="yao-yuan-xing-ji-xing-ji-zhang-li-zhang-ai">药源性急性肌张力障碍</h3>
<ul>
<li><strong>肌张力障碍 dystonia</strong> 是肌肉阵发性痉挛或持续性收缩。对药源性急性肌张力障碍，肌注抗胆碱药有效。慢性肌张力障碍可能是迟发性运动障碍的表现。</li>
</ul>
<h3 id="jing-zuo-bu-neng">静坐不能</h3>
<ul>
<li><strong>静坐不能 akathisia</strong> 体验上表现为不安、紧张、不愉快，行为上表现为不安的运动、原地踏步或踱步。可能难以与原发障碍本身导致的激越或不安运动鉴别。抗胆碱药效果不佳，β阻滞药和苯二氮䓬类药有效，5HT2A阻滞药可能有效。</li>
</ul>
<h3 id="shen-jing-zu-zhi-ji-e-xing-zong-he-zheng">神经阻滞剂恶性综合征</h3>
<ul>
<li><strong>神经阻滞剂恶性综合征 neuroleptic malignant syndrome</strong> 罕见且致命，表现为肌肉极端僵硬、高烧、昏迷或死亡。需要立即停用D2阻滞药，应用肌松药（如丹曲林 dantrolene）和多巴胺激动药，并进行重症监护。</li>
</ul>
<h3 id="chi-fa-xing-yun-dong-zhang-ai">迟发性运动障碍</h3>
<ul>
<li><strong>迟发性运动障碍 tardive dyskinesia, TD</strong> 是长期用D2阻滞药后发病的，可能不可逆的通常面和舌的不随意持续运动，可表现为咀嚼、伸舌、表情痛苦扭曲，或快速、抽动或舞蹈样的肢体运动。</li>
<li><span class=""></span>病理生理<span class=""></span> ：间接通路D2阻滞通过神经重塑机制诱发GABA神经元上D2上调。初期，这种上调是可逆的。一段时间后，这种上调是不可逆的。</li>
<li>可定期进行神经科体检或量表检查。</li>
<li><span class=""></span>治疗<span class=""></span> ：可予90% <a href="/blog/20250919-psychopharmacology-note-chapter-2/#nang-pao-zhuan-yun-ti">VMAT2</a> 阻滞。VMAT2阻滞药包括丁苯那嗪、氘丁苯那嗪、缬苯那嗪。相较其他单胺，它们主要作用于直接和间接通路，影响多巴胺的转运，
从而使多巴胺被MAO代谢。
<ul>
<li><strong>丁苯那嗪 tetrabenazine</strong> 是前药，经羰基还原酶生成4种有活性的二氢丁苯那嗪，均被CYP2D6代谢。发挥VMAT2阻滞作用的主要是+β-二氢丁苯那嗪。浓度亦较大的–α-和-β-二氢丁苯那嗪具有5HT7阻滞性质。
适应症：Huntington病相关的舞蹈症。半衰期短，须tid。副作用包括镇静、DIP和抑郁、自杀风险等。</li>
<li><strong>氘丁苯那嗪 deutetrabenazine</strong> 是被氘代的丁苯那嗪，代谢物同丁苯那嗪，半衰期较丁苯那嗪长（bid），副作用较丁苯那嗪轻微。适应症：与Huntington病有关的舞蹈病；成人迟发性运动障碍。</li>
</ul>
<blockquote>
<p>2025年12月25日，查询得氘丁苯那嗪片价格约为10.691369cny/mg。日剂量12mg~48mg，每月约需3848.89cny~15395.57cny。</p>
</blockquote>
<ul>
<li><strong>缬苯那嗪 valbenazine</strong> 是-α-丁苯那嗪连接了1缬氨酸。代谢：缬氨酸被水解生成-α-丁苯那嗪，经羰基还原酶生成-α-二氢丁苯那嗪，对于VMAT2的选择性最高。适应症、药代学特性类似氘丁苯那嗪，qd。</li>
</ul>
</li>
</ul>
<h2 id="5-5-drugs-targeting-dopamine-d2-receptors-so-called-first-generation-or-conventional-antipsychotics-zuo-yong-yu-d2shou-ti-de-di-yi-dai-dian-xing-kang-jing-shen-bing-yao">5.5 Drugs Targeting Dopamine D2 Receptors: So-Called First Generation or Conventional "Antipsychotics" 作用于D2受体的“第一代/典型抗精神病药”</h2>
<h2 id="5-6-drugs-targeting-serotonin-2a-receptors-with-or-without-simultaneously-targeting-dopamine-d2-receptors-zuo-yong-yu-5ht2ashou-ti-he-fei-zuo-yong-yu-d2shou-ti-de-yao">5.6 Drugs Targeting Serotonin 2A Receptors with or without Simultaneously Targeting Dopamine D2 Receptors 作用于5HT2A受体和/非作用于D2受体的药</h2>
<h2 id="5-7-drugs-targeting-serotonin-1a-receptors-and-dopamine-d2-receptors-as-partial-agonists-5ht1a-d2bu-fen-ji-dong-yao">5.7 Drugs Targeting Serotonin 1A Receptors and Dopamine D2 Receptors as Partial Agonists 5HT1A/D2部分激动药</h2>
<h2 id="5-8-links-between-receptor-binding-properties-of-drugs-used-to-treat-psychosis-and-other-therapeutic-actions-and-side-effects-shou-ti-he-xiao-ying-de-guan-lian">5.8 Links between Receptor Binding Properties of Drugs Used to Treat Psychosis and Other Therapeutic Actions and Side Effects 受体和效应的关联</h2>
<h2 id="5-9-pharmacological-properties-of-selected-individual-first-generation-d2-antagonists-bu-fen-d2zu-zhi-yao-de-yao-li-xue-xing-zhi">5.9 Pharmacological Properties of Selected Individual First-Generation D2 Antagonists 部分D2阻滞药的药理学性质</h2>
<h2 id="5-10-an-overview-of-the-pharmacological-properties-of-individual-5ht2a-d2-antagonists-and-d2-5ht1a-partial-agonists-the-pines-peens-many-dones-and-a-rone-two-pips-and-a-rip-ge-d2-5ht2azu-zhi-yao-he-d2-5ht1abu-fen-ji-dong-yao-de-yao-li-xue-xing-zhi-gai-shu">5.10 An Overview of the Pharmacological Properties of Individual 5HT2A/D2 Antagonists and D2/5HT1A Partial Agonists: The Pines (Peens), Many Dones and a Rone, Two Pips and a Rip 各D2/5HT2A阻滞药和D2/5HT1A部分激动药的药理学性质概述</h2>
<h2 id="5-11-future-treatments-for-schizophrenia-jing-shen-fen-lie-zheng-zhi-liao-zhan-wang">5.11 Future Treatments for Schizophrenia 精神分裂症治疗展望</h2>

</section>

<section>
    2025-12-25
</section>

<section>
    
        # <a href="https://maple-and-stonebridge.github.io/category/bi-ji/"> 笔记 </a>
    
    
        
            # <a href="https://maple-and-stonebridge.github.io/field/yi-xue/"> 医学 </a>
        
            # <a href="https://maple-and-stonebridge.github.io/field/yao-li-xue/"> 药理学 </a>
        
            # <a href="https://maple-and-stonebridge.github.io/field/jing-shen-yao-li-xue/"> 精神药理学 </a>
        
            # <a href="https://maple-and-stonebridge.github.io/field/shen-jing-ke-xue/"> 神经科学 </a>
        
    
    
        
            # <a href="https://maple-and-stonebridge.github.io/tag/kang-jing-shen-bing-yao/"> 抗精神病药 </a>
        
    
</section>


		<footer>
			<p>除非另有说明，本站所有本人创作内容均通过CC0协议释放至公共领域～ Unless other specified, all content by me is released into public domain under CC0 license~~<br /> chsungyesuzuki 2025 no rights reserved</p>
			<a rel="license" href="https://creativecommons.org/publicdomain/zero/1.0/legalcode"><img src="/cc0.png" alt="CC0 Legal Code" /></a>
			<a href="/rss.xml"> <img src="/rss-icon.png" alt="RSS" /> </a>
		</footer>
	</body>
</html>

